Industry updates with Dusko Ilic: December 2024

Written by Dusko ILIC
Cell therapy Clinical manufacturing Clinical trials FDA Gene therapy Industry developments iPSCs MSCs Regulation & policy Report Stem cells

Read highlights from the December installment of Dusko Ilic’s industry news, which discusses the latest developments and news in regenerative medicine and stem cell research, and is published every month in Regenerative Medicine. What happened this month that you were expecting? A monumental step forward for Mesoblast In a groundbreaking moment, the US FDA has officially approved Ryoncil, a mesenchymal stromal/stem cell (MSC) therapy developed by Mesoblast (Australia), for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients. This pivotal decision marks the first time the FDA has sanctioned any MSC therapy, setting a precedent that could reshape...

To view this content, please register now for access

It's completely free